Program
Hepatitis B Virus Antisense Oligonucleotide AHB-137
Also written as “AHB-137”, “AHB-137 injection” and “AHB-137 (24 weeks)”.
Its studies are mostly in Hepatitis B, Chronic, led by 2 companies.
Drug pageHepatitis B Virus Antisense Oligonucleotide AHB-137: every studyAll 11 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Ausper Biopharmaits history only | 86 open or running | phase 3since Aug 12, 2025 | Oct 11, 2023 | Dec 12, 2026phase 2 · NCT07137910 |
| AusperBio Therapeutics | 32 open or running | phase 2since Jan 19, 2026 | Jan 20, 2023 | May 11, 2027phase 2 · NCT07654283 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of AusperBio Therapeutics only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 20, 2023First study: phase 1 study in Hepatitis B, ChronicFirst studyNCT05717686 · 64 enrolled · United States, Hong Kong, New Zealand and more
- Jan 19, 2026Phase 2 study in Hepatitis B, ChronicPhase 2 reachedNCT07370207 · 84 planned · Australia, China, Japan and more
- May 28, 2026Phase 2 study in Hepatitis B, ChronicNCT07654283 · 70 planned · United States, Canada, France and more
Ahead
- May 11, 2027Primary completion: phase 2 study in Hepatitis B, ChronicNCT07654283
- Dec 31, 2028Primary completion: phase 2 study in Hepatitis B, ChronicNCT07370207
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 AusperBio Therapeutics leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07654283Hepatitis B, Chronic · United States, Canada, France and more | 2 | Recruiting | May 11, 2027 | 70 |
| NCT07370207Hepatitis B, Chronic · Australia, China, Japan and more | 2 | Recruiting | Dec 31, 2028 | 84 |
| NCT05717686Hepatitis B, Chronic · United States, Hong Kong, New Zealand and more | 1 | Completed | Jan 7, 2025 | 64 |
How it is read
Names in the registry
- “AHB-137”, 7 entries
- “AHB-137 injection”, 3 entries
- “AHB-137 (24 weeks)”, 1 entry
- “AHB-137 (16 weeks)”, 1 entry
Conditions, from the studies’ own filings
- Hepatitis B, Chronic, 11 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.